Table 4.
Summary of epigenetic drugs for glioma that entered in phase I/II clinical trials.
| Clinical trial | Population | Phase | References | |
|---|---|---|---|---|
| Vorinostat | Vorinostat; | Adult: recurrent GBM; Pediatric: refractory solid tumors | II | Galanis et al. (2009), Fouladi et al. (2010) |
| Vorinostat and temozolomide; | Pediatric: relapsed or refractory primacy CNS tumors; Adult: high-grade glioma | I | Lee et al. (2012), Hummel et al. (2013) | |
| Vorinostat and bortezomib; | Pediatric: refractory or recurrent solid tumors; Adult: advanced malignancies | I/II | Muscal et al. (2013), Schelman et al. (2013) | |
| Vorinostat, erlotinib and radiation; | Adult: GBM (ineffective) | I | Peereboom et al. (2010) | |
| Vorinostat, temozolomide and radiotherapy; | Adult: GBM | I/II | Galanis et al. (2018) | |
| Vorinostat and bevacizumab; | Adult: recurrent World Health Organization Grade 4 malignant glioma | II | Ghiaseddin et al. (2018) | |
| Vorinostat, bevacizumab and temozolomide; | Adult: GBM | I/II | Krauze et al. (2015) | |
| Panobinostat | Panobinostat and bevacizumab; | Adult: recurrent glioblastoma and anaplastic glioma; (no continued accrual) | II | Lee et al. (2015) |
| Panobinostat with fractionated stereotactic re-irradiation; | Adult: recurrent HGG | I | Shi et al. (2016) | |
| Romidepsin | Romidepsin; | Adult: recurrent GBM; (ineffective) | I | Iwamoto et al. (2011) |
| valproic acid | valproic acid; | Pediatric: refractory solid or CNS tumors | I | Su et al. (2011) |
| valproic acid, temozolomide and radiotherapy; | Adult: GBM | II | Krauze et al. (2015) |